Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Bevacizumab extends survival for relapsed and advanced cervical cancer

Dr Krishnansu Sujata Tewari - University of California Irvine Medical Center...

Bevacizumab extends survival for relapsed and advanced cervical cancer ( Dr Krishnansu Sujata Tewari - University of California Irvine Medical Center, USA )

Comment on drug developments in advanced melanoma

Dr Roy Herbst - Yale Cancer Center, New Haven, USA

Comment on drug developments in advanced melanoma ( Dr Roy Herbst - Yale Cancer Center, New Haven, USA )

Brentuximab vedotin in the frontline setting

Dr Stephen Ansell - Mayo Clinic, Rochester, USA

Brentuximab vedotin in the frontline setting ( Dr Stephen Ansell - Mayo Clinic, Rochester, USA )

Lapatinib in combination with chemotherapy in breast cancer

Dr J. Randolph Hecht - UCLA Medical Center, Santa Monica, USA

Lapatinib in combination with chemotherapy in breast cancer ( Dr J. Randolph Hecht - UCLA Medical Center, Santa Monica, USA )

Cetuximab superior to bevacizumab for advanced colorectal cancer

Dr Volke Heinemann - University of Munich Munich, Germany

Cetuximab superior to bevacizumab for advanced colorectal cancer ( Dr Volke Heinemann - University of Munich Munich, Germany )

Improving outcomes of childhood neuroblastoma

Dr Garrett Brodeur - Cancer Center at The Children’s Hospital of Philadelphia...

Improving outcomes of childhood neuroblastoma ( Dr Garrett Brodeur - Cancer Center at The Children’s Hospital of Philadelphia, USA )

Nivolumab produces long-lasting responses in patients with stage IV melanoma

Dr Mario Sznol - Yale Cancer Center, New Haven, USA

Nivolumab produces long-lasting responses in patients with stage IV melanoma ( Dr Mario Sznol - Yale Cancer Center, New Haven, USA )

Delayed relapse of advanced ovarian cancer when treating with pazopanib

Dr Andreas du Bois - Kliniken Essen Mitte, Essen, Germany

Delayed relapse of advanced ovarian cancer when treating with pazopanib ( Dr Andreas du Bois - Kliniken Essen Mitte, Essen, Germany )

Cetuximab superior to bevacizumab for advanced colorectal cancer

Dr Volker Heinemann - University of Munich, Germany

Cetuximab superior to bevacizumab for advanced colorectal cancer ( Dr Volker Heinemann - University of Munich, Germany )

New MEK inhibitor selumetinib is the first effective drug for advanced melanoma...

Dr Richard D. Carvajal - Memorial Sloan-Kettering Cancer Center, New York, USA

New MEK inhibitor selumetinib is the first effective drug for advanced melanoma of the eye ( Dr Richard D. Carvajal - Memorial Sloan-Kettering Cancer Center, New York, USA )

Anti-PD-1 drug nivolumab shows high and durable clinical activity in patients...

Dr Mario Sznol - Yale Cancer Center New Haven, USA

Anti-PD-1 drug nivolumab shows high and durable clinical activity in patients with advanced melanoma ( Dr Mario Sznol - Yale Cancer Center New Haven, USA )

Maintenance therapy with multi-targeted drug pazopanib delays relapse of...

Dr Andreas du Bois - Kliniken Essen Mitte, Germany

Maintenance therapy with multi-targeted drug pazopanib delays relapse of advanced ovarian cancer ( Dr Andreas du Bois - Kliniken Essen Mitte, Germany )

More from ecancer